Enfuvirtide (Fuzeon; Trimeris/Roche), the first in a new class of anti-HIV drugs that inhibit the entry of the virus into cells, was approved by the US FDA in March 2003 for the treatment of HIV-1 infection in treatment-experienced patients. Is it likely to become a blockbuster?